2,493 results match your criteria Endometrial Carcinoma* Obstetrics and Gynecology

"Identification and characterization of endometrial carcinoma with tumor markers HE4 and CA125 in serum and endometrial tissue samples and systematic review of the literature".

J Turk Ger Gynecol Assoc 2021 Jun 8. Epub 2021 Jun 8.

Department of Gynecology Oncology, Hospital Puerta de Hierro, Madrid, Spain.

Objective: The diagnosis of endometrial cancer is made by biopsy sampling with pathological analysis, but it is extremely important to make an accurate diagnosis in order to plan the specific treatment, and we suggest that HE4 in the endometrial tissue and in serum could be tools to make the diagnosis more precise.

Material And Methods: Our prospective study compared patients with endometrial cancer against non-endometrial cancer ones, matched with several variables. The inclusion criteria were females older than 18 years old that accepted to participate in the research study but that had never underwent surgery for other oncological pathologies, whether for ovarian, colon, cervical carcinoma or uterine sarcoma, and none of them had received preoperative chemo or radiotherapy; moreover, they could not have any severe renal or liver pathology. Read More

View Article and Full-Text PDF

Minimally-Invasive Versus Abdominal Hysterectomy for Endometrial Carcinoma With Glandular or Stromal Invasion of Cervix.

Front Oncol 2021 20;11:670214. Epub 2021 May 20.

Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

The purpose of the study was to evaluate the feasibility of laparoscopic approach versus laparotomy in endometrial cancer that extends to the cervix in the form of glandular extension and/or stromal invasion. A retrospective, single-center cohort study was conducted using data between 1995 and 2017 at an urban tertiary academic medical center. We identified patients who were diagnosed with endometrial cancer whose tumor involved the uterine cervix on final pathology. Read More

View Article and Full-Text PDF

Circulating miRNA 27a and miRNA150-5p; a noninvasive approach to endometrial carcinoma.

Mol Biol Rep 2021 Jun 2. Epub 2021 Jun 2.

Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, Champollion street, Al Mesallah Sharq, Al Attarin, Alexandria, Egypt.

The search for novel non-invasive biomarkers such as epigenetic molecular markers is new hope for common and burdensome cancers. We aim to assess serum expression of miRNA 27a and miRNA150-5p in endometrial cancer patients. Serum was drawn for 36 un-intervened endometrial cancer patients scheduled for hysterectomy and 35 controls. Read More

View Article and Full-Text PDF

Targeting Wnt Signaling in Endometrial Cancer.

Cancers (Basel) 2021 May 13;13(10). Epub 2021 May 13.

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

This review presents new findings on Wnt signaling in endometrial carcinoma and implications for possible future treatments. The Wnt proteins are essential mediators in cell signaling during vertebrate embryo development. Recent biochemical and genetic studies have provided significant insight into Wnt signaling, in particular in cell cycle regulation, inflammation, and cancer. Read More

View Article and Full-Text PDF

Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma.

Cell Death Dis 2021 May 26;12(6):544. Epub 2021 May 26.

Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, 250012, Jinan, China.

Progesterone resistance can significantly restrict the efficacy of conservative treatment for patients with endometrial cancer who wish to preserve their fertility or those who suffer from advanced and recurrent cancer. SREBP1 is known to be involved in the occurrence and progression of endometrial cancer, although the precise mechanism involved remains unclear. In the present study, we carried out microarray analysis in progesterone-sensitive and progesterone-resistant cell lines and demonstrated that SREBP1 is related to progesterone resistance. Read More

View Article and Full-Text PDF

Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review.

Int J Gynecol Pathol 2021 May 12. Epub 2021 May 12.

Department of Pathology, Yale-New Haven Hospital, Yale School of Medicine (L.I., K.E.F., V.P.) Department of Obstetrics and Reproductive Sciences, Yale University School of Medicine, New Haven (V.P.) Department of Obstetrics and Gynecology, Yale-New Haven Health, Bridgeport Hospital, Bridgeport, Connecticut (M.C.) Department of Pathology, University of California San Diego, San Diego, California (O.F.).

Patients with germline TP53 mutations are characterized by the occurrence of multiple early-onset malignancies. The characteristic syndrome is Li-Fraumeni syndrome (OMIM # 151623), an autosomal dominant disorder typified by premenopausal breast carcinoma, adrenal cortical tumors, bone and soft tissue sarcomas, leukemias, and tumors of the brain and spinal cord. Gynecologic malignancies are uncommonly reported in families harboring TP53 mutations, and the predominant tumor type reported is ovarian. Read More

View Article and Full-Text PDF

Sentinel lymph node sampling as an alternative to lymphadenectomy in patients with endometrial cancer and obesity.

J Obstet Gynaecol Can 2021 May 10. Epub 2021 May 10.

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.; Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, affiliated with the Hebrew.

Objective: Although its use in endometrial cancer staging is relatively new, sentinel lymph node (SLN) sampling has been shown to be highly accurate and is associated with few complications. However, some studies report lower rates of detection with SLN sampling among patients with obesity. The aim of the current study is to evaluate the feasibility of SLN sampling in endometrial cancer for patients with obesity, and to determine whether omitting lymph node dissection (LND) in surgical staging using SLN sampling impacts oncologic outcomes. Read More

View Article and Full-Text PDF

Dipeptidyl peptidase IV is required for endometrial carcinoma cell proliferation and tumorigenesis via the IL-6/STAT3 pathway.

J Obstet Gynaecol Res 2021 May 9. Epub 2021 May 9.

Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.

Aim: To study the functions and signaling pathways controlled by dipeptidyl peptidase IV (DPPIV) in endometrial carcinoma (EC).

Methods: DPPIV expression in EC cells was detected by flow cytometry, reverse transcription-polymerase chain reaction analysis and Western blot. Interleukin-6 (IL-6) expression in the supernatant was measured by enzyme-linked immunosorbent assay. Read More

View Article and Full-Text PDF

OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma Progression in vitro and in vivo.

Drug Des Devel Ther 2021 30;15:1797-1810. Epub 2021 Apr 30.

Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Purpose: OSU-03012 is a celecoxib derivative lacking cyclooxygenase-2 inhibitory activity and a potent PDK1 inhibitor which has been shown to inhibit tumor growth in various ways. However, the role of OSU-03012 in endometrial carcinoma (EC) in which the PI3K/Akt signaling pathway highly activated has not been studied. Here, we determined the potency of OSU-03012 in suppressing EC progression in vitro and in vivo, and studied the underlined mechanisms. Read More

View Article and Full-Text PDF

The PVT1/miR-612/CENP-H/CDK1 axis promotes malignant progression of advanced endometrial cancer.

Am J Cancer Res 2021 15;11(4):1480-1502. Epub 2021 Apr 15.

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University Sanhao Street, Shenyang, People's Republic of China.

Our previous study introduced the oncogenic role of the long non-coding RNA plasmacytoma variant translocation 1 (PVT1) in endometrial cancer (EC). In this study, we aimed to construct a PVT1-centered competing endogenous RNA (ceRNA) network to outline a regulatory axis that might promote the malignant progression of advanced EC. Raw Uterine Corpus Endometrial Carcinoma (UCEC) datasets were collected from The Cancer Genome Atlas (TCGA) database and used for construction of the PVT1-centered ceRNA network. Read More

View Article and Full-Text PDF

Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.

Curr Oncol Rep 2021 May 3;23(7):75. Epub 2021 May 3.

Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, The James Cancer Hospital and Solove Research Institute, M-210 Starling-Loving, 320 West 10th Avenue, Columbus, OH, 43210-3078, USA.

Purpose Of Review: This article will discuss the recent data on the prognostic significance of molecular classification of endometrial carcinoma, as well as its impact on directing treatment decisions.

Recent Findings: Molecular classification has emerged as a complement to the current paradigm of endometrial cancer (EC) risk stratification. POLE mutations appear to portend favorable prognoses, but data are insufficient to indicate withholding treatment based on this signature. Read More

View Article and Full-Text PDF

Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT.

Int Immunopharmacol 2021 Apr 29;97:107705. Epub 2021 Apr 29.

Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai 200080, People's Republic of China; Department of Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, People's Republic of China. Electronic address:

Uterine corpus endometrial carcinoma (UCEC) is the most prevalent gynecologic cancer in developed countries and lacks efficient therapeutic strategies. Artesunate (ART), a well-modified derivate of artemisinin, exerts potent anti-cancer effects apart from its classical anti-malaria feature. Autophagy is a universal double-edged process in cell survival, and CD155 is a novel immune checkpoint highly expressed in numerous cancers. Read More

View Article and Full-Text PDF

Endometrial carcinoma originating in an isthmocele.

Int J Gynecol Cancer 2021 May;31(5):799-800

Radiology, Hospital Universitario de Donostia, San Sebastian, País Vasco, Spain.

View Article and Full-Text PDF

[Correlation between the primary tumor size of endometrial carcinoma and lymph node metastasis and recurrence].

Zhonghua Fu Chan Ke Za Zhi 2021 Apr;56(4):264-270

Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.

To investigate the clinical significance of the primary tumor size in patients with endometrial carcinoma (EC). A total of 385 patients with EC admitted to Peking University People's Hospital from January 2006 to December 2016 with complete follow up data were selected, whose tumor size data before biopsy were retrospectively studied. (1) The mean diameter of the primary tumor was (3. Read More

View Article and Full-Text PDF

The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?

Reprod Sci 2021 Apr 15. Epub 2021 Apr 15.

The Department of Obstetrics and Gynecology, Ain Shams University, Cairo, Egypt.

Five to 10% of patients with stage IA, grade 1 or 2, endometrioid adenocarcinoma subsequently develop locoregional or distant recurrence. These patients have significantly reduced 5-year survival rates and salvage therapy success rates as low as 40%. The aim of this review is to highlight knowledge gaps that could further refine the risk categories of endometrial carcinoma (EC) and guide future randomized trials of adjuvant therapy for low-risk EC. Read More

View Article and Full-Text PDF

Phyllodes tumor of the vulva: A case report and literature review highlighting a novel manifestation of Cowden syndrome.

Gynecol Oncol Rep 2021 May 23;36:100752. Epub 2021 Mar 23.

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.

Cowden syndrome is a rare hereditary cancer syndrome characterized by a germline mutation which results in an increased risk of developing breast, thyroid, and endometrial carcinoma, as well as widespread benign hamartomas. Phyllodes tumor (PT) is a rare fibroepithelial tumor that accounts for less than 1% of all breast tumors. As mammary-type glands can be found in the anogenital region, PTs can rarely arise in this location. Read More

View Article and Full-Text PDF

Benign metastasising leiomyoma with endometrial carcinoma, with a differential diagnosis of metastatic lung cancer.

BMJ Case Rep 2021 Apr 12;14(4). Epub 2021 Apr 12.

Department of Obstetrics and Gynecology, St Luke's International University, Chuo-ku, Tokyo, Japan.

Benign metastasising leiomyoma (BML) is a rare disease in which histologically benign uterine fibroids spread throughout the body. It is thought to originate from the hematogenous metastasis of myoma cells following myomectomy. To date, BML has been noted in patients with respiratory symptoms, even during regular checkups. Read More

View Article and Full-Text PDF

Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy.

Int J Gynecol Cancer 2021 Jun 8;31(6):852-858. Epub 2021 Apr 8.

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois, USA

Background: Chemotherapy response score (CRS) applied to interval debulking specimens quantifies histopathologic response to neoadjuvant chemotherapy in patients with advanced ovarian carcinoma and correlates with progression-free and overall survival.

Objective: To investigate whether the chemotherapy response score could be applied to interval debulking specimens in patients with advanced endometrial carcinoma and be a prognostic indicator.

Methods: The study included patients with clinical stage III-IV endometrial carcinoma who received neoadjuvant chemotherapy followed by interval debulking surgery. Read More

View Article and Full-Text PDF

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis.

Diagn Pathol 2021 Apr 8;16(1):28. Epub 2021 Apr 8.

Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan.

Background: This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma.

Methods: Between 1989 and 2017, patients with endometrial carcinoma who underwent total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either or both immunochemical expression of mesothelin and CA125 and clinicopathological features were retrospectively examined. Read More

View Article and Full-Text PDF

Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.

Gynecol Oncol 2021 Jun 31;161(3):795-801. Epub 2021 Mar 31.

Department of Public Health, University of Naples Federico II, Naples, Italy.

Objective: Deficient expression of mismatch repair proteins (MMR) has been suggested to be a predictor of resistance of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) to conservative treatment.

Aims: To assess the predictive value of MMR immunohistochemistry in patients conservatively treated for AEH and EEC, and to calculate its predictive accuracy.

Materials And Methods: All patients with AEH or EEC conservatively treated with hysteroscopic resection plus progestins in two referral centers from January 2004 to July 2019 were retrospectively assessed. Read More

View Article and Full-Text PDF

Overexpression of MYBL2 predicts poor prognosis and promotes oncogenesis in endometrial carcinoma.

Eur J Histochem 2021 Mar 30;65(2). Epub 2021 Mar 30.

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province.

Endometrial cancer (EC) is the most common gynecologic malignancy and still remains clinically challenging. We aimed to explore the potential biomarkers of EC and provide a theoretical basis for early screening and targeted therapy. The available transcriptome data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were analyzed to identify differentially expressed genes. Read More

View Article and Full-Text PDF

Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit.

Brachytherapy 2021 Mar 26. Epub 2021 Mar 26.

Department of Radiation Oncology, Stanford University; Stanford, CA. Electronic address:

Objectives: To determine which patients with stage III endometrial cancer receiving adjuvant chemotherapy derive benefit from the addition of vaginal brachytherapy, as stage III is a highly heterogeneous population with substantial variations in practice.

Methods: Patients with FIGO stage III endometrial carcinoma diagnosed 2004-2016 who underwent at least total hysterectomy and adjuvant multiagent chemotherapy were identified in the National Cancer Database. The primary outcome was overall survival according to receipt of brachytherapy, stratified by histologic type, pathological features, and status of pelvic external beam radiotherapy (EBRT), and analyzed using the Kaplan-Meier method and Cox multivariable regression. Read More

View Article and Full-Text PDF

How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?

Horm Mol Biol Clin Investig 2020 Dec 18;42(1):105-111. Epub 2020 Dec 18.

1st Department of Obstetrics and Gynecology, Alexandra Hospital, Gynecologic Oncology Unit, University of Athens, Athens, Greece.

The aim of this study is to evaluate and compare outcomes of patients with mixed and pure endometrial carcinomas (MEC). We reviewed data of patients with MEC, endometroid (EC), serous (SC), and clear cell (CC) carcinomas between 2002 and 2015. Overall survival (OS) and disease-free (DF) survival rates were evaluated, according to the percentage of histologic components. Read More

View Article and Full-Text PDF
December 2020

Preoperative Assessment of Cervical Involvement in Endometrial Cancer by Transvaginal Ultrasound and Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis.

Ultraschall Med 2021 Mar 23. Epub 2021 Mar 23.

Obstetrics and Gynecology, Università degli Studi di Cagliari, Italy.

Objective:  To compare the diagnostic accuracy of transvaginal ultrasound (TVS) and magnetic resonance imaging (MRI) for detecting cervical infiltration by endometrial carcinoma using meta-analysis assessment.

Methods:  An extensive search of papers comparing TVS and MRI for assessing cervical infiltration in endometrial cancer in the same set of patients was performed in Medline (Pubmed), Web of Science, and the Cochrane Database. Quality was assessed using QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies-2). Read More

View Article and Full-Text PDF

Endometrial polyps. An evidence-based diagnosis and management guide.

Eur J Obstet Gynecol Reprod Biol 2021 May 13;260:70-77. Epub 2021 Mar 13.

Department of Obstetrics, Gynecology and Reproductive Sciences, Minimally Invasive Gynecology Division, University of Miami, Miller School of Medicine, 1321 NW 14(th) Street Suite 201, Miami, FL 33136, USA. Electronic address:

Objective: To provide an updated practice guideline for the management of patients with endometrial polyps.

Materials And Methods: A committee of six expert researchers draw the recommendations according to AGREE II Reporting Guideline. An electronic search was performed querying the following databases MEDLINE (accessed through PubMed), Scopus, PROSPERO, EMBASE, CINAHL, Cochrane Library (including the Cochrane Database of Systematic Reviews), Scielo. Read More

View Article and Full-Text PDF

LncRNA-ZXF1 regulates P21 expression in endometrioid endometrial carcinoma by managing ubiquitination-mediated degradation and miR-378a-3p/PCDHA3 axis.

Mol Oncol 2021 Mar 9. Epub 2021 Mar 9.

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.

Long noncoding RNAs (lncRNAs) have a profound effect on biological processes in various malignancies. However, few studies have investigated their functions and specific mechanisms in endometrial cancer. In this study, we focused on the role and mechanism of lncRNA-ZXF1 in endometrial cancer. Read More

View Article and Full-Text PDF

Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas.

Ginekol Pol 2021 Mar 10. Epub 2021 Mar 10.

Department of Obstetrics and Gynecology, Çukurova University, School of Medicine, Adana, Turkey.

Objectives: Grade 3 endometrioid adenocarcinomas (G3 EAC), type two endometrial carcinomas (Type 2 EC), and also uterine carcinosarcomas (UCS) are considered as high-grade endometrial adenocarcinomas. The aim of this study was to compare the clinicopathologic features and survival of patients with UCS, G3 EAC, Type2 EC.

Material And Methods: We included two hundred and thirty-five patients in this study. Read More

View Article and Full-Text PDF

A Risk Signature with Nine Stemness Index-Associated Genes for Predicting Survival of Patients with Uterine Corpus Endometrial Carcinoma.

J Oncol 2021 6;2021:6653247. Epub 2021 Mar 6.

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China.

Purpose: To identify mRNA expression-based stemness index- (mRNAsi-) related genes and build an mRNAsi-related risk signature for endometrial cancer.

Methods: We collected mRNAsi data of endometrial cancer samples from The Cancer Genome Atlas (TCGA) and analyzed their relationship with the main clinicopathological characteristics and prognosis of endometrial cancer patients. We screened the top 50% of the genes in TCGA for weighted gene correlation network analysis (WGCNA) to explore mRNAsi-related gene sets. Read More

View Article and Full-Text PDF

Aberrant Claudin-6-Adhesion Signaling Promotes Endometrial Cancer Progression via Estrogen Receptor α.

Mol Cancer Res 2021 Mar 16. Epub 2021 Mar 16.

Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Cell adhesion proteins not only maintain tissue integrity, but also possess signaling abilities to organize diverse cellular events in a variety of physiologic and pathologic processes; however, the underlying mechanism remains obscure. Among cell adhesion molecules, the claudin (CLDN) family is often aberrantly expressed in various cancers, but the biological relevance and molecular basis for this observation have not yet been established. Here, we show that high CLDN6 expression accelerates cellular proliferation and migration in two distinct human endometrial cancer cell lines . Read More

View Article and Full-Text PDF

Lymphovascular space invasion in endometrial carcinoma: Tumor size and location matter.

Surg Oncol 2021 Mar 6;37:101541. Epub 2021 Mar 6.

Department of Obstetrics and Gynecology. University Hospital 12 de Octubre. Madrid, Spain. Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. Universidad Complutense de Madrid, Madrid, Spain.

Objective: To analyze histological factors possibly associated with lymphovascular space invasion (LVSI) and to determine which of those can act as independent surrogate markers.

Methods: Retrospective cohort study performed between January 2001 and December 2014. LVSI was defined as the presence of tumor cells inside a space completely surrounded by endothelial cells. Read More

View Article and Full-Text PDF